Sex Differences in Trajectories of LDL Cholesterol Control in Chronic Coronary Syndromes
BACKGROUND AND AIMS: Sex differences in the longitudinal evolution of low-density lipoprotein cholesterol (LDL-C) management among patients with chronic coronary syndromes (CCS) are not well known. METHODS: In the international CLARIFY registry, which included patients with CCS, LDL-C levels were monitored annually over the 5-year follow-up period. The analysis included patients with available LDL-C measurement at baseline. Target LDL-C was set at 100 mg/dL, in line with prevailing recommendations at enrolment. Sex-specific differences in LDL-C were adjusted for age and geographical region. Impact of longitudinal LDL-C was assessed using mean LDL-C up to the primary outcome of interest or last follow-up defined as cardiovascular (CV) death or MI during 5-year follow-up, evaluated using multivariable analysis. RESULTS: Of 32,376 patients in the initial cohort, women were less likely to have LDL-C measurement available at baseline (aOR 1.12, 95%CI 1.06-1.18, p<0.001). Of the 21,925 patients with LDL-C measurement at baseline, 21.6% were women. At inclusion, women were less likely to receive statins (82.7% vs. 85.4%, p<0.001) and more likely to fail reaching the LDL-C target (45.6% vs. 37.4%; aOR 1.47, 95%CI 1.38-1.58, p<0.001). This disparity persisted across the 5-year follow-up (p<0.001 for every year). Overall, women were more likely than men to never reach the target LDL-C during follow-up (20.7% vs. 15.8%; aOR 1.44, 95% CI 1.32-1.56, p<0.001). Higher mean LDL-C during follow-up was associated with an increased risk of the primary outcome (aHR 1.06 per 10 mg/dL increase, 95% CI 1.04-1.07, p<0.001). CONCLUSION: Women with CCS were less likely to have LDL-C measurement available at baseline, to receive lipid-lowering drugs and consistently exhibited poorer LDL-C control than men over the 5-year follow-up. Given the association of LDL-C and adverse CV outcomes, targeted interventions to close the sex gap in secondary prevention are needed.
Authors
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- Gaspard Suc (ORCID: https://orcid.org/0000-0003-2273-1528)
- Ian Ford (ORCID: https://orcid.org/0000-0001-5927-1823)
- Grégory Ducrocq (ORCID: https://orcid.org/0000-0003-4069-1128)
- Jean‐Claude Tardif (ORCID: https://orcid.org/0000-0002-8200-8983)
- Michał Tendera (ORCID: https://orcid.org/0000-0002-0812-6113)
- Jules Mesnier (ORCID: https://orcid.org/0000-0002-2131-6763)
- Louis Giovachini (ORCID: https://orcid.org/0009-0003-3562-813X)
- Roberto Ferrari (ORCID: https://orcid.org/0000-0003-2046-9175)
- Kim M Fox
Institutions
- Inserm (FR)
- Medical University of Silesia (PL)
- Université Paris Cité (FR)
- Montreal Heart Institute (CA)
- Sorbonne Paris Cité (FR)
- Royal Brompton Hospital (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Maria Cecilia Hospital (IT)
- Hôpital Bichat-Claude-Bernard (FR)
- Alliance nationale pour les sciences de la vie et de la santé (FR)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-08-17
- DOI
- https://doi.org/10.1093/eurjpc/zwag419
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00